Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Impact of different PSMA PET-based eligibility criteria on outcome of [Lu]Lu-PSMA radioligand therapy using [F]rhPSMA-7/[F]rhPSMA-7.3 (Flotufolastat)
Saved in:
| Published in: | EJNMMI Research |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Impact of different PSMA PET-based eligibility criteria on outcome of [Lu]Lu-PSMA radioligand therapy using [F]rhPSMA-7/[F]rhPSMA-7.3 (Flotufolastat)
- Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer
- Can chatGPT-4o reliably standardize PSMA PET/CT and PET/MRI reports using PROMISE V2 criteria? - An exploratory study
- 18F-PSMA-1007 in recurrent prostate cancer, a new frontier in prostate cancer PET imaging
- Integrated Ga-PSMA PET/MRI models improve prostate cancer diagnosis and ISUP stratification, especially in the low-PSA cohort
- Prostate specific membrane antigen (PSMA) targeting polymer-peptide conjugates
- Metastatic Merkel Cell Carcinoma Incidentally Detected on PSMA PET/CT in a Patient With Metastatic Prostate Cancer